Renato Mantegazza

List of Publications by Year in Descending Order

273 papers	9,053 citations	52 h-index	82 g-index
304 ext. papers	10,625 ext. citations	5.4 avg, IF	5.63 L-index

#	Paper	IF	Citations
273	Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.. *Neurotherapeutics*, **2022**, 1	6.4	2
272	Novel Cell-Based Assay for Alpha-3 Nicotinic Receptor Antibodies Detects Antibodies Exclusively in Autoimmune Autonomic Ganglionopathy.. *Neurology: Neuroimmunology and NeuroInflammation*, **2022**, 9,	9.1	1
271	Quantitative Muscle MRI Protocol as Possible Biomarker in Becker Muscular Dystrophy. *Clinical Neuroradiology*, **2021**, 31, 257-266	2.7	7
270	Therapeutic efficacy of 3,4-Diaminopyridine phosphate on neuromuscular junction in Pompe disease. *Biomedicine and Pharmacotherapy*, **2021**, 137, 111357	7.5	1
269	Dysregulation of Muscle-Specific MicroRNAs as Common Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from Animal Models and Human Patients. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
268	MyomiRs and their multifaceted regulatory roles in muscle homeostasis and amyotrophic lateral sclerosis. *Journal of Cell Science*, **2021**, 134,	5.3	3
267	Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurology, The*, **2021**, 20, 526-536	24.1	29
266	Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. *Neurology*, **2021**, 96, e610-e618	6.5	16
265	Next-generation sequencing application to investigate skeletal muscle channelopathies in a large cohort of Italian patients. *Neuromuscular Disorders*, **2021**, 31, 336-347	2.9	4
264	Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups. *Frontiers in Immunology*, **2021**, 12, 633167	8.4	3
263	Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG). *BMJ Open*, **2021**, 11, e048198	3	0
262	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. *Muscle and Nerve*, **2021**, 64, 662-669	3.4	1
261	Iatrogenic Kaposi sarcoma in myasthenia gravis: learnings from two case reports. *Neurological Sciences*, **2021**, 42, 2081-2083	3.5	1
260	Multiomic elucidation of a coding 99-mer repeat-expansion skeletal muscle disease. *Acta Neuropathologica*, **2020**, 140, 231-235	14.3	6
259	miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids. *Frontiers in Immunology*, **2020**, 11, 142	8.4	17
258	Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction. *Cells*, **2020**, 9,	7.9	2
257	Eculizumab for the treatment of myasthenia gravis. *Expert Opinion on Biological Therapy*, **2020**, 20, 991-998	3.4	4

256	Employment in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis. *Neuroepidemiology*, **2020**, 54, 304-312	5.4	2
255	Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients. *Biomedicines*, **2020**, 8,	4.8	15
254	Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. *Journal of the Neurological Sciences*, **2020**, 412, 116803	3.2	81
253	Complement Inhibition for the Treatment of Myasthenia Gravis. *ImmunoTargets and Therapy*, **2020**, 9, 317-331	9	11
252	Glycogen storage in a zebrafish Pompe disease model is reduced by 3-BrPA treatment. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2020**, 1866, 165662	6.9	4
251	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). *Lancet Neurology, The*, **2020** , 19, 970-971	24.1	45
250	Clinical and Molecular Spectrum of Myotonia and Periodic Paralyses Associated With Mutations in in a Large Cohort of Italian Patients. *Frontiers in Neurology*, **2020**, 11, 646	4.1	3
249	Consistent improvement with eculizumab across muscle groups in myasthenia gravis. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1327-1339	5.3	6
248	From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research. *Frontiers in Neurology*, **2020**, 11, 981	4.1	7
247	Reliability and Repeatability Analysis of Indices to Measure Gait Deterioration in MS Patients during Prolonged Walking. *Sensors*, **2020**, 20,	3.8	3
246	Pharmacogenetic and pharmaco-miR biomarkers for tailoring and monitoring myasthenia gravis treatments. *Expert Review of Precision Medicine and Drug Development*, **2020**, 5, 317-329	1.6	2
245	Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 1166-1174	5.5	32
244	**2019**,		3
243	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. *Lancet Neurology, The*, **2019**, 18, 259-268	24.1	74
242	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. *Neurology*, **2019**, 92, e2661-e2673	6.5	90
241	Eculizumab improves fatigue in refractory generalized myasthenia gravis. *Quality of Life Research*, **2019**, 28, 2247-2254	3.7	19
240	FM19G11-Loaded Gold Nanoparticles Enhance the Proliferation and Self-Renewal of Ependymal Stem Progenitor Cells Derived from ALS Mice. *Cells*, **2019**, 8,	7.9	13
239	Aging-associated genes and microRNAs: a contribution to myogenic program dysregulation in oculopharyngeal muscular dystrophy. *FASEB Journal*, **2019**, 33, 7155-7167	0.9	6

238	Hyperexcitability in Cultured Cortical Neuron Networks from the G93A-SOD1 Amyotrophic Lateral Sclerosis Model Mouse and its Molecular Correlates. *Neuroscience*, **2019**, 416, 88-99	3.9	10
237	MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine. *Pharmacological Research*, **2019**, 148, 104388	10.2	10
236	Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. *Journal of the Neurological Sciences*, **2019**, 407, 116419	3.2	8
235	Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome. *Expert Review of Clinical Pharmacology*, **2019**, 12, 1013-1018	3.8	7
234	Italian recommendations for the diagnosis and treatment of myasthenia gravis. *Neurological Sciences*, **2019**, 40, 1111-1124	3.5	23
233	Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. *Muscle and Nerve*, **2019**, 60, 14-24	3.4	76
232	Therapeutic Effect of Bifidobacterium Administration on Experimental Autoimmune Myasthenia Gravis in Lewis Rats. *Frontiers in Immunology*, **2019**, 10, 2949	8.4	7
231	Diagnosis and treatment of myasthenia gravis. *Current Opinion in Rheumatology*, **2019**, 31, 623-633	5.3	15
230	Italian recommendations for diagnosis and management of congenital myasthenic syndromes. *Neurological Sciences*, **2019**, 40, 457-468	3.5	16
229	Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. *Journal of Medical Genetics*, **2019**, 56, 293-300	5.8	16
228	Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate. *Pharmacological Research*, **2019**, 141, 224-235	10.2	12
227	Older age, higher perceived disability and depressive symptoms predict the amount and severity of work-related difficulties in persons with multiple sclerosis. *Disability and Rehabilitation*, **2019**, 41, 2255-2263	2.4	3
226	Botulinum toxin type A affects the transcriptome of cell cultures derived from muscle biopsies of controls and spastic patients. *Toxicology in Vitro*, **2018**, 50, 124-136	3.6	1
225	Toll-like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?. *Annals of the New York Academy of Sciences*, **2018**, 1413, 11-24	6.5	18
224	Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?. *Annals of the New York Academy of Sciences*, **2018**, 1413, 49-58	6.5	22
223	When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. *Therapeutic Advances in Neurological Disorders*, **2018**, 11, 1756285617749134	6.6	74
222	Exosomes and exosomal miRNAs from muscle-derived fibroblasts promote skeletal muscle fibrosis. *Matrix Biology*, **2018**, 74, 77-100	11.4	37
221	Up-regulation of Toll-like receptors 7 and 9 and its potential implications in the pathogenic mechanisms of LMNA-related myopathies. *Nucleus*, **2018**, 9, 398-409	3.9	9

220	Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation. *Acta Neurologica Scandinavica*, **2018**, 137, 623-625	3.8	13
219	Paraneoplastic autoimmune diseases in patients with thymic malignancies: a favorable, but not independent, prognostic factor. *Mediastinum*, **2018**, 2, 41-41	0.5	
218	Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats. *Oncotarget*, **2018**, 9, 22269-22287	3.3	22
217	Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study. *SAGE Open Medicine*, **2018**, 6, 2050312118819013	2.4	18
216	Myasthenia gravis: from autoantibodies to therapy. *Current Opinion in Neurology*, **2018**, 31, 517-525	7.1	25
215	Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration?. *CNS Drugs*, **2018**, 32, 653-660	6.7	1
214	Difficulties in adjustment to multiple sclerosis: vulnerability and unpredictability of illness in the foreground. *Disability and Rehabilitation*, **2017**, 39, 897-903	2.4	19
213	Long-term cardiovascular autonomic and clinical changes after immunoglobulin G immunoadsorption therapy in autoimmune autonomic ganglionopathy. *Journal of Hypertension*, **2017**, 35, 1513-1520	1.9	5
212	A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis. *Neurology*, **2017**, 89, 189-195	6.5	8
211	Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. *Journal of Neurology*, **2017**, 264, 1854-1863	5.5	38
210	A longitudinal DTI and histological study of the spinal cord reveals early pathological alterations in G93A-SOD1 mouse model of amyotrophic lateral sclerosis. *Experimental Neurology*, **2017**, 293, 43-52	5.7	16
209	Validation of the italian version of the 15-item Myasthenia Gravis Quality-of-Life questionnaire. *Muscle and Nerve*, **2017**, 56, 716-720	3.4	8
208	Coexistence of CLCN1 and SCN4A mutations in one family suffering from myotonia. *Neurogenetics*, **2017**, 18, 219-225	3	13
207	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurology, The*, **2017**, 16, 976-986	24.1	278
206	A novel ABCC6 haplotype is associated with azathioprine drug response in myasthenia gravis. *Pharmacogenetics and Genomics*, **2017**, 27, 51-56	1.9	5
205	Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients. *Neurological Sciences*, **2017**, 38, 1927-1931	3.5	4
204	Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?. *Oncotarget*, **2017**, 8, 95432-95449	3.3	13
203	Biobank of Cells, Tissues and DNA from Patients with Neuromuscular Diseases: An Indispensable link between Clinical Centers and the Scientific Community. *Open Journal of Bioresources*, **2017**, 4,	0.9	3

202	Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis. *Journal of the Neurological Sciences*, **2016**, 369, 139-140	3.2	9
201	A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients. *Immunobiology*, **2016**, 221, 1227-36	3.4	22
200	Psychosocial difficulties of individuals with multiple sclerosis: the PARADISE-24 questionnaire. *International Journal of Rehabilitation Research*, **2016**, 39, 339-345	1.8	7
199	Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita: a paradigm to understand and treat ion channelopathies. *FASEB Journal*, **2016**, 30, 3285-3295	0.9	15
198	Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection. *Immunobiology*, **2016**, 221, 516-27	3.4	36
197	Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen. *Journal of Neuroimmunology*, **2016**, 292, 108-15	3.5	37
196	Multiple Sclerosis Questionnaire for Job Difficulties (MSQ-Job): definition of the cut-off score. *Neurological Sciences*, **2016**, 37, 777-80	3.5	2
195	Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients. *Life Sciences*, **2016**, 145, 127-36	6.8	19
194	Comparison of Diffusion MRI Acquisition Protocols for the In Vivo Characterization of the Mouse Spinal Cord: Variability Analysis and Application to an Amyotrophic Lateral Sclerosis Model. *PLoS ONE*, **2016**, 11, e0161646	3.7	5
193	Animal models of myasthenia gravis: utility and limitations. *International Journal of General Medicine*, **2016**, 9, 53-64	2.3	22
192	Cognitive function alone is a poor predictor of health-related quality of life in employed patients with MS: results from a cross-sectional study. *Clinical Neuropsychologist*, **2016**, 30, 201-15	4.4	7
191	Validation of the MG-DIS: a disability assessment for myasthenia gravis. *Journal of Neurology*, **2016**, 263, 871-882	5.5	13
190	Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness. *Journal of the Neurological Sciences*, **2016**, 368, 402-7	3.2	12
189	Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies. *Clinical Immunology*, **2016**, 173, 133-146	9	4
188	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. *Neurobiology of Aging*, **2016**, 47, 218.e1-218.e9	5.6	29
187	Validation of the Besta Neurological Institute rating scale for myasthenia gravis. *Muscle and Nerve*, **2016**, 53, 32-7	3.4	10
186	Up-regulation of neural and cell cycle-related microRNAs in brain of amyotrophic lateral sclerosis mice at late disease stage. *Molecular Brain*, **2015**, 8, 5	4.5	36
185	MuSK autoantibodies in myasthenia gravis detected by cell based assay--A multinational study. *Journal of Neuroimmunology*, **2015**, 284, 10-7	3.5	48

184	Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2015**, 1852, 1451-64	6.9	60
183	ClC-1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype-phenotype correlation. *Journal of Physiology*, **2015**, 593, 4181-99	3.9	21
182	CHARACTERIZATION BY MOLECULAR MARKERS OF 'POMPIANA' NATURAL CITRUS HYBRID CULTIVATED IN SARDINIA. *Acta Horticulturae*, **2015**, 165-172	0.3	9
181	Development and validation of the multiple sclerosis questionnaire for the evaluation of job difficulties (MSQ-Job). *Acta Neurologica Scandinavica*, **2015**, 132, 226-34	3.8	8
180	ClC-1 chloride channels: state-of-the-art research and future challenges. *Frontiers in Cellular Neuroscience*, **2015**, 9, 156	6.1	38
179	The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. *Neurobiology of Aging*, **2015**, 36, 1766.e1-1766.e3	5.6	13
178	Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. *Trials*, **2015**, 16, 184	2.8	24
177	The European LEMS Registry: Baseline Demographics and Treatment Approaches. *Neurology and Therapy*, **2015**, 4, 105-24	4.6	23
176	In vivo quantitative magnetization transfer imaging correlates with histology during de- and remyelination in cuprizone-treated mice. *NMR in Biomedicine*, **2015**, 28, 327-37	4.4	61
175	Human CD14+ cells loaded with Paclitaxel inhibit in vitro cell proliferation of glioblastoma. *Cytotherapy*, **2015**, 17, 310-9	4.8	11
174	Autoimmune Ion Channel Disorders of the Peripheral Nervous System **2015**, 457-468		
173	Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. *Neurological Sciences*, **2014**, 35, 515-20	3.5	16
172	Altered miRNA expression is associated with neuronal fate in G93A-SOD1 ependymal stem progenitor cells. *Experimental Neurology*, **2014**, 253, 91-101	5.7	27
171	A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. *Journal of Autoimmunity*, **2014**, 52, 139-45	15.5	187
170	Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse. *Cell and Tissue Research*, **2014**, 356, 427-43	4.2	18
169	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. *BMC Neurology*, **2014**, 14, 65	3.1	43
168	Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. *Journal of Autoimmunity*, **2014**, 52, 74-89	15.5	52
167	Autophagy, inflammation and innate immunity in inflammatory myopathies. *PLoS ONE*, **2014**, 9, e111490	3.7	30

166	European database for myasthenia gravis: a model for an international disease registry. *Neurology*, **2014**, 83, 189-91	6.5	7
165	Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis. *Disability and Rehabilitation*, **2014**, 36, 546-55	2.4	12
164	LMNA-associated myopathies: the Italian experience in a large cohort of patients. *Neurology*, **2014**, 83, 1634-44	6.5	45
163	VAV1 and BAFF, via NFB pathway, are genetic risk factors for myasthenia gravis. *Annals of Clinical and Translational Neurology*, **2014**, 1, 329-39	5.3	22
162	LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. *Annals of Clinical and Translational Neurology*, **2014**, 1, 80-7	5.3	65
161	Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial. *Health Expectations*, **2014**, 17, 36-48	3.7	11
160	Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.. *Journal of Clinical Oncology*, **2014**, 32, 2087-2087	2.2	1
159	Orphan drugs to treat myasthenia gravis. *Expert Opinion on Orphan Drugs*, **2013**, 1, 373-384	1.1	1
158	Duchenne muscular dystrophy fibroblast nodules: a cell-based assay for screening anti-fibrotic agents. *Cell and Tissue Research*, **2013**, 352, 659-70	4.2	13
157	Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption. *Journal of Neuroimmunology*, **2013**, 262, 19-26	3.5	9
156	Etiology of myasthenia gravis: innate immunity signature in pathological thymus. *Autoimmunity Reviews*, **2013**, 12, 863-74	13.6	64
155	Marked phenotypic variability in two siblings with congenital myasthenic syndrome due to mutations in MUSK. *Journal of Neurology*, **2013**, 260, 2894	5.5	22
154	Percutaneous vertebroplasty in a series of myasthenic patients with steroid-induced symptomatic vertebral fractures. *Neurological Sciences*, **2013**, 34, 773-6	3.5	2
153	Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis. *Journal of Neuroimmunology*, **2013**, 258, 41-50	3.5	3
152	P20.4 Antithetic role of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy. *Neuromuscular Disorders*, **2013**, 23, 839-840	2.9	2
151	A large cohort of myotonia congenita probands: novel mutations and a high-frequency mutation region in exons 4 and 5 of the CLCN1 gene. *Journal of Human Genetics*, **2013**, 58, 581-7	4.3	32
150	Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study. *European Journal of Human Genetics*, **2013**, 21, 630-6	5.3	32
149	Complete stable remission and autoantibody specificity in myasthenia gravis. *Neurology*, **2013**, 80, 188-96	6.5	43

148	Factors related to difficulties with employment in patients with multiple sclerosis: a review of 2002-2011 literature. *International Journal of Rehabilitation Research*, **2013**, 36, 105-11	1.8	86
147	A new thiopurine s-methyltransferase haplotype associated with intolerance to azathioprine. *Journal of Clinical Pharmacology*, **2013**, 53, 67-74	2.9	20
146	The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. *OncoImmunology*, **2013**, 2, e23401	7.2	42
145	Comparative neuronal differentiation of self-renewing neural progenitor cell lines obtained from human induced pluripotent stem cells. *Frontiers in Cellular Neuroscience*, **2013**, 7, 175	6.1	26
144	Sleep breathing disorders in 40 Italian patients with Myotonic dystrophy type 1. *Neuromuscular Disorders*, **2012**, 22, 219-24	2.9	37
143	Patient registries: useful tools for clinical research in myasthenia gravis. *Annals of the New York Academy of Sciences*, **2012**, 1274, 107-13	6.5	5
142	Recommendations for myasthenia gravis clinical trials. *Muscle and Nerve*, **2012**, 45, 909-17	3.4	86
141	Autoimmune mechanisms in myasthenia gravis. *Current Opinion in Neurology*, **2012**, 25, 621-9	7.1	52
140	Treatment of myasthenia gravis: focus on pyridostigmine. *Clinical Drug Investigation*, **2011**, 31, 691-701	3.2	56
139	Current and emerging therapies for the treatment of myasthenia gravis. *Neuropsychiatric Disease and Treatment*, **2011**, 7, 151-60	3.1	52
138	Human neurotrophin receptor p75NTR defines differentiation-oriented skeletal muscle precursor cells: implications for muscle regeneration. *Journal of Neuropathology and Experimental Neurology*, **2011**, 70, 133-42	3.1	22
137	Osteopontin is highly expressed in severely dystrophic muscle and seems to play a role in muscle regeneration and fibrosis. *Histopathology*, **2011**, 59, 1215-28	7.3	41
136	Fibroblasts from the muscles of Duchenne muscular dystrophy patients are resistant to cell detachment apoptosis. *Experimental Cell Research*, **2011**, 317, 2536-47	4.2	25
135	Variable disease severity in Saudi Arabian and Sudanese families with c.3924 + 2 T > C mutation of LAMA2. *BMC Research Notes*, **2011**, 4, 534	2.3	7
134	Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: a longitudinal MRI study. *Experimental Neurology*, **2011**, 231, 30-7	5.7	67
133	Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. *Neurological Sciences*, **2011**, 32, 841-7	3.5	30
132	The thymus in myasthenia gravis: Site of "innate autoimmunity"?. *Muscle and Nerve*, **2011**, 44, 467-84	3.4	46
131	Epstein-Barr virus in myasthenia gravis thymus: a matter of debate. *Annals of Neurology*, **2011**, 70, 519	9.4	7

130	Importance of Shank3 protein in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapses. *Journal of Biological Chemistry*, **2011**, 286, 34839-50	5.4	145
129	Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. *Neurology*, **2011**, 76, 2079-88	6.5	64
128	Myasthenia gravis. *Autoimmune Diseases*, **2011**, 2011, 697575	2.9	1
127	Inflammation and epstein-barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis. *Autoimmune Diseases*, **2011**, 2011, 213092	2.9	18
126	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. *Multiple Sclerosis Journal*, **2010**, 16, 100-11	5	38
125	Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis. *Journal of Immunology*, **2010**, 185, 5656-67	5.3	21
124	Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. *Multiple Sclerosis Journal*, **2010**, 16, 1237-47	5	22
123	Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis. *Neurology*, **2010**, 74, 1118-26	6.5	48
122	Calsequestrin and junctin immunoreactivity in hexagonally cross-linked tubular arrays myopathy. *Neuromuscular Disorders*, **2010**, 20, 326-9	2.9	3
121	Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. *Annals of Neurology*, **2010**, 67, 726-38	9.4	79
120	The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study. *Journal of Neurology*, **2010**, 257, 98-102	5.5	44
119	Identification of previously unreported mutations in CHRNA1, CHRNE and RAPSN genes in three unrelated Italian patients with congenital myasthenic syndromes. *Journal of Neurology*, **2010**, 257, 1119-23	5.5	10
118	Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis. *Neurological Sciences*, **2010**, 31, 41-5	3.5	37
117	Social support and self-efficacy in patients with Myasthenia Gravis: a common pathway towards positive health outcomes. *Neurological Sciences*, **2010**, 31, 231-5	3.5	22
116	Construct and concurrent validation of the MG-QOL15 in the practice setting. *Muscle and Nerve*, **2010**, 41, 219-26	3.4	51
115	Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables. *Journal of Neurology, Neurosurgery and Psychiatry*, **2009**, 80, 790-3	5.5	46
114	ICF in neurology: functioning and disability in patients with migraine, myasthenia gravis and Parkinson's disease. *Disability and Rehabilitation*, **2009**, 31 Suppl 1, S88-99	2.4	18
113	Central core disease and susceptibility to malignant hyperthermia in a single family. *Journal of Neurology*, **2009**, 256, 1161-3	5.5	

112	Risk factors for tumor occurrence in patients with myasthenia gravis. *Journal of Neurology*, **2009**, 256, 1221-7	5.5	26
111	Anaphylaxis to a self-peptide in the absence of mast cells or histamine. *Laboratory Investigation*, **2009**, 89, 398-405	5.9	6
110	Allergy and multiple sclerosis: a population-based case-control study. *Multiple Sclerosis Journal*, **2009**, 15, 899-906	5	26
109	Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2009**, 10, 410-5		34
108	Identification of international classification of functioning, disability and health relevant categories to describe functioning and disability of patients with myasthenia gravis. *Disability and Rehabilitation*, **2009**, 31, 2041-6	2.4	18
107	Disability and functional profiles of patients with myasthenia gravis measured with ICF classification. *International Journal of Rehabilitation Research*, **2009**, 32, 167-72	1.8	19
106	Increased Il-8 Levels in the Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis. *European Journal of Inflammation*, **2009**, 7, 39-44	0.3	3
105	Immunotherapy responsive startle with antibodies to voltage gated potassium channels. *BMJ Case Reports*, **2009**, 2009,	0.9	2
104	BDNF and its receptors in human myasthenic thymus: implications for cell fate in thymic pathology. *Journal of Neuroimmunology*, **2008**, 197, 128-39	3.5	14
103	Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients. *Journal of Neuroimmunology*, **2008**, 201-202, 104-10	3.5	22
102	Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. *Journal of Neuroimmunology*, **2008**, 201-202, 237-44	3.5	63
101	Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor. *Neuromuscular Disorders*, **2008**, 18, 678-80	2.9	23
100	CD4+CD25+ regulatory T cells specific for a thymus-expressed antigen prevent the development of anaphylaxis to self. *Journal of Immunology*, **2008**, 180, 4433-40	5.3	12
99	Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. *Journal of Immunology*, **2008**, 180, 2696-703	5.3	10
98	An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. *Neurology*, **2008**, 71, 400-6	6.5	203
97	The kinesin superfamily motor protein KIF4 is associated with immune cell activation in idiopathic inflammatory myopathies. *Journal of Neuropathology and Experimental Neurology*, **2008**, 67, 624-32	3.1	16
96	Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. *Annals of Neurology*, **2007**, 61, 219-27	9.4	381
95	Immunotherapy responsive startle with antibodies to voltage gated potassium channels. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 1281-90	5.5	7

94	Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-beta in modulating proliferation. *International Immunology*, **2007**, 19, 1063-74	4.9	49
93	Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. *Journal of Neuroimmunology*, **2006**, 175, 77-86	3.5	104
92	A key regulatory role for histamine in experimental autoimmune encephalomyelitis: disease exacerbation in histidine decarboxylase-deficient mice. *Journal of Immunology*, **2006**, 176, 17-26	5.3	67
91	Myasthenia gravis remission and anti-AChR ab reduction after immunosuppressive and anti-neoplastic therapy in a patient with thymic Hodgkin's disease. *Journal of Neurology*, **2006**, 253, 1241-2	3.5	6
90	Inflammatory Myopathies **2006**, 119-134		
89	Decorin and biglycan expression is differentially altered in several muscular dystrophies. *Brain*, **2005**, 128, 2546-55	11.2	75
88	Sequential antibodies to potassium channels and glutamic acid decarboxylase in neuromyotonia. *Neurology*, **2005**, 64, 1290-3	6.5	27
87	Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. *American Journal of Pathology*, **2005**, 167, 129-39	5.8	54
86	Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. *Brain*, **2005**, 128, 454-71	11.2	358
85	LAMA2 gene analysis in congenital muscular dystrophy: new mutations, prenatal diagnosis, and founder effect. *Archives of Neurology*, **2005**, 62, 1582-6		28
84	Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. *International Immunology*, **2004**, 16, 559-65	4.9	44
83	Unusual neurophysiological and immunological findings in myasthenia gravis: a case report. *Journal of the Peripheral Nervous System*, **2004**, 9, 92-7	4.7	6
82	Response to Dr. Jaretzki's letter on video-assisted thoracoscopic extended thymectomy. *Journal of the Neurological Sciences*, **2004**, 217, 235-236	3.2	4
81	Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy in non-thymomatous myasthenia gravis patients. *Journal of the Neurological Sciences*, **2004**, 217, 233-4; author reply 235-6	3.2	9
80	Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. *Journal of Immunology*, **2004**, 172, 2697-703	5.3	56
79	Rasmussen's encephalitis: update on pathogenesis and treatment. *Expert Review of Neurotherapeutics*, **2003**, 3, 835-43	4.3	2
78	Molecular heterogeneity in acute renal allograft rejection and DNA microarrays. *New England Journal of Medicine*, **2003**, 349, 2269	59.2	2
77	Antimyelin antibodies in multiple sclerosis. *New England Journal of Medicine*, **2003**, 349, 2269-71; author reply 2269-71	59.2	3

76	Analysis of SjTREC levels in thymus from MG patients and normal children. *Annals of the New York Academy of Sciences*, **2003**, 998, 270-4	6.5	2
75	Expression of transforming growth factor-beta1 in thymus of myasthenia gravis patients: correlation with pathological abnormalities. *Annals of the New York Academy of Sciences*, **2003**, 998, 278-83	6.5	8
74	Immunization with rat-, but not Torpedo-derived 97-116 peptide of the AChR alpha-subunit induces experimental myasthenia gravis in Lewis rat. *Annals of the New York Academy of Sciences*, **2003**, 998, 391-4	6.5	5
73	Effect on T cell recognition and immunogenicity of alanine-substituted peptides corresponding to 97-116 sequence of the rat AChR alpha-subunit. *Annals of the New York Academy of Sciences*, **2003**, 998, 395-8	6.5	4
72	Myasthenia gravis (MG): epidemiological data and prognostic factors. *Annals of the New York Academy of Sciences*, **2003**, 998, 413-23	6.5	109
71	Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. *Journal of Neuroimmunology*, **2003**, 142, 130-6	3.5	109
70	Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. *Journal of the Neurological Sciences*, **2003**, 212, 31-6	3.2	107
69	Experience with immunomodulatory treatments in Rasmussen's encephalitis. *Neurology*, **2003**, 61, 1807-10	6.9	133
68	IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset. *Journal of Neuroimmunology*, **2002**, 122, 94-9	3.5	21
67	Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. *Journal of Neuroimmunology*, **2002**, 131, 179-85	3.5	130
66	Is the CACNA1A gene involved in familial migraine with aura?. *Neurological Sciences*, **2002**, 23, 1-5	3.5	42
65	Similar binding to glutamate receptors by Rasmussen and partial epilepsy patients' sera. *Neurology*, **2002**, 59, 1998-2001	6.5	20
64	Analysis of antibody gene rearrangement, usage, and specificity in chronic focal encephalitis. *Neurology*, **2002**, 58, 709-16	6.5	21
63	Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. *Neuromuscular Disorders*, **2002**, 12, 828-35	2.9	48
62	Chapter 15 Clinical Trials in Muscle Disorders. *Blue Books of Practical Neurology*, **2001**, 25, 311-325		1
61	Anti-neuronal nicotinic receptor antibodies in MG patients with thymoma. *Journal of Neuroimmunology*, **2001**, 113, 142-5	3.5	4
60	GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. *Neurology*, **2001**, 57, 1511-4	6.5	140
59	Labeling of rat neurons by anti-GluR3 IgG from patients with Rasmussen encephalitis. *Neurology*, **2001**, 57, 324-7	6.5	20

58	Antibodies against neuronal nicotinic receptor subtypes in neurological disorders. *Journal of Neuroimmunology*, **2000**, 102, 89-97	3.5	34
57	Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. *Journal of Neuropathology and Experimental Neurology*, **2000**, 59, 164-9	3.1	67
56	Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. *International Immunology*, **2000**, 12, 1329-35	4.9	166
55	Identification of three novel mutations in the major human skeletal muscle chloride channel gene (CLCN1), causing myotonia congenita. *Human Mutation*, **1999**, 14, 447	4.7	18
54	Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. *Neuromuscular Disorders*, **1999**, 9, 28-33	2.9	112
53	Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. *Journal of the Neurological Sciences*, **1999**, 164, 64-71	3.2	63
52	Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. *Journal of Clinical Investigation*, **1999**, 104, 1287-95	15.9	43
51	Epidemiological study of myasthenia gravis in the province of Reggio Emilia, Italy. *European Journal of Epidemiology*, **1998**, 14, 381-7	12.1	20
50	Identification of a novel HLA class II association with DQB1*0502 in an Italian myasthenic population. *Annals of the New York Academy of Sciences*, **1998**, 841, 355-9	6.5	22
49	Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma. *Annals of the New York Academy of Sciences*, **1998**, 841, 538-41	6.5	31
48	Oral administration of an immunodominant TAChR epitope modulates antigen-specific T cell responses in mice. *Annals of the New York Academy of Sciences*, **1998**, 841, 568-71	6.5	2
47	Video-assisted thoracoscopic extended thymectomy (VATET) in myasthenia gravis. Two-year follow-up in 101 patients and comparison with the transsternal approach. *Annals of the New York Academy of Sciences*, **1998**, 841, 749-52	6.5	24
46	Plasma treatment in diseases of the neuromuscular junction. *Annals of the New York Academy of Sciences*, **1998**, 841, 803-10	6.5	9
45	A new non-radioactive method for the screening and prenatal diagnosis of myotonic dystrophy patients. *Journal of Neurology*, **1998**, 245, 289-93	5.5	9
44	The expression of co-stimulatory and accessory molecules on cultured human muscle cells is not dependent on stimulus by pro-inflammatory cytokines: relevance for the pathogenesis of inflammatory myopathy. *Journal of Neuroimmunology*, **1998**, 85, 52-8	3.5	19
43	Long-term selective IgG immuno-adsorption improves Rasmussen's encephalitis. *Neurology*, **1998**, 51, 302-5	6.5	94
42	Transforming growth factor-beta 1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate. *Journal of Neuropathology and Experimental Neurology*, **1997**, 56, 479-84	3.1	52
41	Emerging treatments in myopathies. *European Neurology*, **1997**, 38, 222-9	2.1	3

40	Concomitant deficiency of beta- and gamma-sarcoglycans in 20 alpha-sarcoglycan (adhalin)-deficient patients: immunohistochemical analysis and clinical aspects. *Acta Neuropathologica*, **1997**, 94, 28-35	14.3	36
39	Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. *Journal of Neurology*, **1997**, 244, 277-87	5.5	45
38	Detection of antibody classes and subpopulations in myasthenia gravis patients using a new nonradioactive enzyme immunoassay. *Muscle and Nerve*, **1997**, 20, 800-8	3.4	8
37	Aspects of Clinical Preparation of Thymectomy in Myasthenic Cases with or without Thymoma and the Clinico-Biological Follow-up of the Thymectomized Patients **1997**, 319-327		
36	Major histocompatibility complex class II molecule expression on muscle cells is regulated by differentiation: implications for the immunopathogenesis of muscle autoimmune diseases. *Journal of Neuroimmunology*, **1996**, 68, 53-60	3.5	20
35	Clinical heterogeneity of adhalin deficiency. *Annals of Neurology*, **1996**, 39, 196-202	9.4	14
34	Lack of mRNA and dystrophin expression in DMD patients three months after myoblast transfer. *Neuromuscular Disorders*, **1995**, 5, 291-5	2.9	55
33	T-cell receptor-CDR3 sequences of polymyositis muscle-infiltrating T-lymphocytes indicate a conventional antigen as target. *Annals of the New York Academy of Sciences*, **1995**, 756, 414-7	6.5	1
32	T-cell infiltration in polymyositis is characterized by coexpression of cytotoxic and T-cell-activating cytokine transcripts. *Annals of the New York Academy of Sciences*, **1995**, 756, 418-20	6.5	13
31	Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype. *Journal of the Neurological Sciences*, **1995**, 132, 146-55	3.2	29
30	DMD and BMD in the same family due to distinct mutations. *American Journal of Medical Genetics Part A*, **1995**, 59, 501-5		12
29	Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. *Journal of Clinical Investigation*, **1995**, 96, 1137-44	15.9	227
28	Changes in peripheral blood lymphocyte subset frequencies in myasthenia gravis patients are related to immunosuppression. *Journal of Neurology*, **1994**, 241, 218-22	5.5	9
27	Protein-A immunoadsorption in immunosuppression-resistant myasthenia gravis. *Lancet, The*, **1994**, 343, 124	40	17
26	Cellular aspects of myositis. *Current Opinion in Rheumatology*, **1994**, 6, 568-74	5.3	27
25	Very small dystrophin molecule in a family with a mild form of Becker dystrophy. *Neuromuscular Disorders*, **1993**, 3, 65-70	2.9	15
24	Immune activation in myasthenia gravis: soluble interleukin-2 receptor, interferon-gamma and tumor necrosis factor-alpha levels in patients\serum. *Journal of Neuroimmunology*, **1993**, 48, 33-6	3.5	20
23	HLA-A2-restricted T-cell line recognizing an epitope of the human acetylcholine receptor. *Annals of the New York Academy of Sciences*, **1993**, 681, 276-9	6.5	2

22	Immunosuppressive treatments. Their efficacy on myasthenia gravis patientsNoutcome and on the natural course of the disease. *Annals of the New York Academy of Sciences*, **1993**, 681, 594-602	6.5	23
21	Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection. *Journal of Clinical Investigation*, **1993**, 91, 2880-6	15.9	120
20	A short plasma exchange protocol is effective in severe myasthenia gravis. *Journal of Neurology*, **1991**, 238, 103-7	5.5	55
19	Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. *Journal of the Neurological Sciences*, **1991**, 106, 213-20	3.2	103
18	Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma. *Neurology*, **1991**, 41, 1128-32	6.5	66
17	A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. *Journal of Neurology* , **1990**, 237, 339-44	5.5	93
16	HTLV-I sequences are not detected in peripheral blood genomic DNA or in brain cDNA of multiple sclerosis patients. *Annals of Neurology*, **1990**, 28, 574-7	9.4	14
15	Prospects for specific immunotherapy in myasthenia gravis. *FASEB Journal*, **1990**, 4, 2726-31	0.9	31
14	Increased incidence of certain TCR and HLA genes associated with myasthenia gravis in Italians. *Journal of Autoimmunity*, **1990**, 3, 431-40	15.5	18
13	Chloroquine myopathy and myasthenia-like syndrome. *Muscle and Nerve*, **1988**, 11, 114-9	3.4	35
12	Anti AChR antibody: relevance to diagnosis and clinical aspects of myasthenia gravis. *Italian Journal of Neurological Sciences*, **1988**, 9, 141-5		12
11	Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. *Journal of Neurology*, **1988**, 235, 449-53	5.5	100
10	Immunoblot analysis of antiAChR antibodies in myasthenia gravis. *Journal of Neuroimmunology*, **1988**, 17, 258	3.5	78
9	Use of immunoadsorbent columns for antiacetylcholine receptor antibody removal from plasma of myasthenia gravis patients. *Plasma Therapy and Transfusion Technology*, **1988**, 9, 73-75		1
8	Synthetic peptides and their antibodies in the analysis of the acetylcholine receptor. *Annals of the New York Academy of Sciences*, **1987**, 505, 256-71	6.5	12
7	The course of myasthenia gravis in patients treated with corticosteroids, azathioprine, and plasmapheresis. *Annals of the New York Academy of Sciences*, **1987**, 505, 517-25	6.5	15
6	Species specificity of anti-acetylcholine receptor antibodies elicited by synthetic peptides. *Biochemistry*, **1987**, 26, 4611-6	3.2	9
5	Thymectomy for myasthenia gravis: a fourteen-year experience. *Italian Journal of Neurological Sciences*, **1985**, 6, 425-8		1

4	New antigen for antibody detection in myasthenia gravis. *Neurology*, **1984**, 34, 374-7	6.5	26
3	Myasthenia gravis: prolonged treatment with steroids. *Neurology*, **1984**, 34, 170-4	6.5	88
2	Multiple sclerosis and migration in Italy: a case/control study. Preliminary reports. *Acta Neurologica Scandinavica*, **1981**, 64, 361-9	3.8	1
1	Exosomes and exosomal miRNAs from muscle-derived fibroblasts promote skeletal muscle fibrosis		2